DUBLIN--(BUSINESS WIRE)--The "Lupus Nephritis - Epidemiology Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
This Lupus Nephritis - Epidemiology Forecast-2032 report delivers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Diagnosis
LN is diagnosed through urine and blood tests and a kidney biopsy. One of the first signs of LN is blood in the urine or extremely foamy urine. High blood pressure and swelling in the feet also might indicate lupus nephritis. The blood test measures creatinine, a waste product from the normal breakdown of muscles in the body that is removed from the blood by kidneys.
Lupus Nephritis Epidemiology
The epidemiology section provides insights about the historical and current Lupus Nephritis patient pool and forecasted trends for individual seven major countries.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Lupus Nephritis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total diagnosed cases of Lupus Nephritis was 209,166 cases in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Lupus Nephritis epidemiology [segmented as Total Prevalent Cases of Lupus Nephritis, Total Diagnosed Cases of Lupus Nephritis, Total Treated Cases of Lupus Nephritis] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Lupus Nephritis Epidemiology
The epidemiology segment also provides the Lupus Nephritis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
KOL-Views
To keep up with the current Lupus Nephritis patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Lupus Nephritis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Lupus Nephritis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Lupus Nephritis
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Lupus Nephritis Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Lupus Nephritis Epidemiology Segmentation
Key Topics Covered:
1. Key Insights
2. Executive Summary
3. Lupus Nephritis: Market Overview at a Glance
3.1. Total Market Share (%) Distribution of Lupus Nephritis in 2019
3.2. Total Market Share (%) Distribution of Lupus Nephritis in 2032
4. Lupus Nephritis: Disease Background and Overview
4.1. Introduction
4.2. Causes
4.3. Risk Factors
4.4. Symptoms
4.5. Other Clinical Manifestation
4.6. Prognosis of lupus nephritis
4.7. Clinical presentation of lupus nephritis
4.8. Pathogenesis
4.9. Classification
4.9.1. LN World Health Organization 1964 Classification
4.9.2. LN World Health Organization 1964 Classification
4.9.3. World Health Organization (WHO) morphologic classification of lupus nephritis (modified in 1982)
4.9.4. LN World Health Organization 1964 Classification
4.9.5. International Society of Nephrology (ISN) and Renal Pathology Society (RPS) 2003 Classification for LN
4.9.6. LN World Health Organization 1964 Classification
4.10. Diagnosis
5. Epidemiology and Patient Population
5.1. Key Findings
6. 7MM Total Prevalent Patient Population of LN
7. Country Wise-Epidemiology of Lupus Nephritis
7.1. United States
7.1.1. Assumptions and Rationale
7.1.2. Total Prevalent Population of Lupus Nephritis
7.1.3. Total Diagnosed Population of Lupus Nephritis
7.1.4. Gender-Specific Prevalent Population of Lupus Nephritis
7.1.5. Class- Specific cases of Lupus Nephritis
7.1.6. Clinical Manifestations of Lupus Nephritis
7.2. EU5 Countries
7.2.1. Assumptions and Rationale
7.3. Germany
7.4. France
7.5. Italy
7.6. United Kingdom
7.7. Spain
7.8. Japan
8. Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jedjkg
